FDA doubles dosage of Covid-19 monoclonal antibody, raising concerns about access and supply
The USDA released a statement advising individuals that received Evusheld to go back and get a second dose of the drug as soon as possible. Evusheld is a monoclonal antibody that is given to people that are immunocompromised and cannot be vaccinated due to medical reasons. Originally, patients were to receive 150 milligrams of the drug, but it has now been doubled due to new findings from ongoing studies. Now that the treatment has doubled, this raises concerns about scarcity. Stay tuned for additional updates.
To read more, click here.